Bax R P
Department of Clinical Research and Development, SmithKline Beecham Pharmaceuticals, Harlow, Essex, England.
Clin Infect Dis. 1997 Jan;24 Suppl 1:S151-3. doi: 10.1093/clinids/24.supplement_1.s151.
The development of new antibiotics has been successful in significantly reducing morbidity and mortality. With increasing use there has occurred an increase in antibiotic resistance but not a parallel increase in new agents with significantly improved spectrum of activity. Without concerted action from the pharmaceutical industry, physicians, academia, health care providers, and governments, the prospects look gloomy.
